Marco Donia: Modified Classification for Progressive Disease in Immunotherapy
Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a recent paper on LinkedIn by Jonas Saal, Hematologist and Oncologist at University Hospital Bonn, published in JAMA Oncology:
“Modified Classification for Progressive Disease in Immunotherapy.
A new study introduces an improved framework to classify progressive disease (PD) in patients undergoing immune checkpoint inhibitor (ICI) treatment.
This approach addresses the challenges posed by RECIST 1.1 criteria, simplifying complex outcomes for better decision-making.
Key Findings:
Progressive Disease (PD) Classification:
- Low-risk: Progression in existing lesions only.
- Intermediate-risk: New lesions appear without progression in existing ones.
- High-risk: Progression in existing lesions alongside new lesions.
Impact on Survival: 6-month post-progression survival (PPOS):
- 90% for low-risk PD.
- 26% for high-risk PD.
Validation: Across multiple tumor types, including renal cell carcinoma, lung cancer, and melanoma, through analysis of five phase 3 clinical trials.
Clinical Implications:
- Simplifies survival prediction and aids shared decision-making for treatment adjustments.
- Low-risk PD: Supports treatment beyond progression in select cases.
- High-risk PD: Highlights the need for alternative therapies.
My take home:
This intuitive classification could streamline PD assessments for treatment beyond progression vs changing therapy. While the results are promising, real-world validation is essential.
Learn more about RECIST.
Details on Immune RECIST.”
Authors:
More posts featuring Marco Donia.
Marco Donia is a Senior Consultant, Clinician-Scientist, and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark. He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen.
Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1-resistant tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023